clinical trial · NCT06729853
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
Shanton Pharma Pte. Ltd.·phase2·active not recruiting·n = 32
GoutHyperuricemiaSAP-001
brief summary
This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects will be enrolled in one of 4 groups (8 subjects per group) with varying degrees of renal function.
started
Apr 24, 2024
primary completion
Jan 17, 2025
completion
Apr 28, 2025
last updated
Dec 11, 2024
official title
A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol